TrialLeukemia2021

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.

Richard A Larson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.